Transcatheter Closure of Patent Ductus Arteriosus in Extremely Premature Newborns: Early Results and Midterm Follow-Up

详细信息    查看全文

• 作者：Evan M. Zahn ; MD ; ^{evan.zahn@cshs.org} ; Daniel Peck ; MD ; Alistair Phillips ; MD ; Phillip Nevin ; RN ; Kaylan Basaker ; CVT ; Charles Simmons ; MD ; Marion E. McRae ; NP ; Tracy Early ; MA ; Ruchira Garg ; MD
• 关键词：device occlusion ; patent ductus arteriosus ; premature newborn
• 刊名：JACC: Cardiovascular Interventions
• 出版年：2016
• 出版时间：12 December 2016
• 年：2016
• 卷：9
• 期：23
• 页码：2429-2437
• 全文大小：873 K
• 卷排序：9

文摘

The goal of this study was to describe early and midterm outcomes of extremely premature newborns (EPNs) who underwent transcatheter echocardiographically guided patent ductus arteriosus (PDA) closure.BackgroundSurgical ligation of PDA in EPNs confers significant risk for procedural morbidity and adverse long-term outcomes.MethodsThe Amplatzer Vascular Plug II was used in all cases. Post-ligation syndrome was defined using previously published parameters. Patients were followed at pre-specified intervals, and prospectively collected data were reviewed.ResultsTranscatheter closure was attempted in 24 EPNs (mean procedural age 30 days [range 5 to 80 days], mean procedural weight 1,249 g [range 755 to 2,380 g]) and was successful in 88%. The 3 procedural failures were related to the development of left pulmonary artery (LPA) stenosis caused by the device, and all devices were removed uneventfully. Complications included 2 instances of device malposition, resolved with device repositioning, and 1 instance of LPA stenosis, requiring an LPA stent. There were no procedural deaths, cases of post-ligation syndrome, residual PDA, or device embolization. Survival to discharge was 96% (23 of 24), with a single late death unrelated to the procedure. After a median follow-up period of 11.1 months, all patients were alive and well, with no residual PDA or evidence of LPA or aortic coarctation.ConclusionsThis newly described technique can be performed safely with a high success rate and minimal procedural morbidity in EPNs. Early and midterm follow-up is encouraging. Future efforts should be directed toward developing specific devices for this unique application.